Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
Authors
Alina Pascale
Hepato-Biliary Center, Paul Brousse Hospital, APHP, Villejuif, France
Alina Pascale , Marc Antoine Allard , Amal Benamar , Francis Levi , Rene Adam , Olivier Rosmorduc
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 457)
DOI
10.1200/JCO.2024.42.3_suppl.457
Abstract #
457
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
First Author: Robin Kate Kelley
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
First Author: Leijuan Gan
Poster
2023 ASCO Annual Meeting
Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system.
First Author: Lauren Diaz Boyle
Poster
2021 Genitourinary Cancers Symposium
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
First Author: Jeffrey Graham